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a b s t r a c t
One of the ﬁrst methods to encapsulate drugs within polymer nanospheres was developed by Fessi and
coworkers in 1989 and consisted of one-step nanoprecipitation based on solvent displacement. However,
proteins arepoorly encapsulatedwithinpolymernanoparticles using thismethodbecauseof their limited sol-
ubility in organic solvents. To overcome this limitation, we developed a two-step nanoprecipitation method
and encapsulated various proteins with high efﬁciency into poly(lactic-co-glycolic)acid (PLGA) nanospheres
(NP). In this method, a protein nanoprecipitation step is used ﬁrst followed by a second polymer nanopre-
cipitation step. Two model enzymes, lysozyme and α-chymotrypsin, were used for the optimization of the
method.We obtained encapsulation efﬁciencies of>70%, an amount of buffer-insoluble protein aggregates of
typically<2%, and a high residual activity of typically>90%. The optimum conditions identiﬁed for lysozyme
were used to successfully encapsulate cytochrome c(Cyt-c), an apoptosis-initiating basic protein of similar
size, to verify reproducibility of the encapsulation procedure. The size of the Cyt-c loaded-PLGA nanospheres
was around 300–400nm indicating the potential of the delivery system to passively target tumors. Cell via-
bility studies, using a human cervical cancer cell line (HeLa), demonstrate excellent biocompatibility of the
PLGA nanoparticles. PLGA nanoparticles carrying encapsulated Cyt-c were not efﬁcient in causing apoptosis
presumably because PLGA nanoparticles are not efﬁciently taken up by the cells. Future systems will have
to be optimized to ascertain efﬁcient cellular uptake of the nanoparticles by, e.g., surface modiﬁcation with
receptor ligands.
c© 2012 Elsevier B.V. All rights reserved.1. Introduction
Nanoparticles can be used to design or even comprise excellent
drug delivery systems [1,2]. For example, due to the enhanced per-
meability and retention (EPR) effect, nanoparticles can passively tar-
get tumors and accumulate in them [1,3]. Nanoparticles can increase
the stability of drugs including proteins in blood, are secreted less
readily by the kidney, which often results in increased therapeutic
efﬁcacy and can reduce side effects of other therapies. [1,3–8]. In this
work, we focus on nanoparticles comprised of poly(lactic-co-glycolic
acid) (PLGA) because the polymer is an intensely studied material in
the ﬁeld of sustained release, has received FDA approval in various
invasive applications including drug delivery, and is biocompatible,
biodegradable, and non-toxic [2,9–11].
A promising method to obtain PLGA nanoparticles is by nanopre-
cipitation, aprocedure thatwasdevelopedbyFessi andcoworkers and* Corresponding author. Tel.: +1 787 764 0000x4781; fax: +1 787 756 8242.
E-mail address: kai.griebenow@gmail.com (K. Griebenow).
2211-2863/$ - see front matter c© 2012 Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.rinphs.2012.11.001enables production of particles in the 100–300 nm range [12]. Advan-
tages of this method include that it is a single step not requiring ex-
tended shearing/stirring rates, soniﬁcation, or high temperatures. The
method is characterized by the absence of an oil–aqueous interface
which is detrimental to protein structure and function [13,14]. How-
ever, the nanoprecipitation method, as developed, is mostly suitable
for hydrophobic compounds that are soluble in ethanol or acetone,
but display limited solubility in water. For example, Barichello et al.
obtained encapsulation efﬁciencies close to 100% with the lipophilic
drugs cindomethacin and cyclosporine A, but less than 15% for the
hydrophilic drugs vacomycin and phenobarbital [15].
In order to overcome these limitations, the original nanoprecip-
itation method was modiﬁed by Bilati et al. using a wide range of
water-miscible organic solvents [13]. This work provided evidence
that nanoprecipitation could occur with solvents other than acetone
or ethanol, and that an accurate solvent and non-solvent selection
could be extended to enable nanoprecipitation of more hydrophilic
drugs. It remains difﬁcult to identify two suitable solvents, because
one of them must be able to dissolve both drug and polymer (sol-
vent or diffusing phase), while the polymer should be insoluble in the
second solvent (non-solvent or dispersing phase). In a second study,
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Fig. 1. Scheme of the encapsulation of proteins into PLGA nanospheres by two-step
nanoprecipitation.
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shey selected the water-miscible organic solvent DMSO as the dif-
using phase and tested the encapsulation using the model proteins
ysozyme and insulin [16]. The authorswere able to load nanospheres
fﬁciently with lysozyme, but not with insulin. Note that the study
y Bilati et al. [13] did not include protein stability experiments. This
s troublesome because DMSO is reported to irreversible unfold most
roteins [17,18] and it is thereforeunlikely that thedevelopedmethod
s generally applicable.
We set out to overcome the aforementioned problems by develop-
ng a new nanoencapsulation procedure. Overcoming the obstacles in
rotein encapsulation by one-step nanoprecipitation is challenging.
irst, it is difﬁcult to ﬁnd a common solvent for the quite hydrophobic
LGA and the hydrophilic protein. Second, the organic solvent can
nduce deleterious protein structural and functional loss. We there-
ore designed a novel two-step nanoprecipitation method (Fig. 1) and
ested its capability to encapsulate two model proteins, lysozyme
nd α-chymotrypsin, into PLGA nanospheres. The two model pro-
eins were chosen because we have employed them frequently in
he past to follow encapsulation procedures [14]. While lysozyme is
uite stable,α-chymotrypsin easily denatures and is an excellent sen-
or for the potential impact of the procedure on protein structure and
unction [14]. The ﬁrst step in this new method consists in solvent-
nduced nanoprecipitation of the protein. Then, encapsulation was
ccomplished by a subsequent polymer nanoprecipitation step. In
ontrast to Bilati et al. who used DMSO to dissolve the proteins [16],
e suspended the dehydrated protein nanoparticles obtained by sol-
ent precipitation in organic solvents incapable of dissolvingproteins,
ut capable of dissolving PLGA. Results from solid-state protein for-
ulations show that in the absence of water, protein conformational
obility is reduced so that the stability of proteins in contact with
he organic solvent is enhanced [14,19,20]. Results fromnon-aqueous
nzymology support this assumption [14,21–23]. Bydeterminingpro-
ein aggregation and function after encapsulation, we tested whether
ur assumptions with respect to the advantages of reduced protein
tructural mobility were correct or not.
After optimizing the methodology, we employed the processing
arameters established for lysozyme to encapsulate an unrelated ba-
ic protein of similar size, horse heart cytochrome c(Cyt-c), in PLGAnanospheres to test the potential of the drug delivery system for ap-
plications in cancer treatment [24]. Cyt-c is an important mediator of
apoptosiswhen it is released from themitochondria to the cytoplasm.
This process normally takes place in response to DNA damage, but in
many cancer cells it is inhibited. The targeted delivery of Cyt c directly
to the cytoplasm of cancer cell could selectively initiate apoptosis.
2. Materials and methods
2.1. Chemicals
Poly(d,l-lactic-co-glycolic)acid (PLGA) with a co-polymer ratio of
50:50 and 65:35 [lactide-to-glycolide] and a MW of 10,000 (not end-
capped), was from Lakeshore Biomaterials (Birmingham, AL). TheMW
is an average value determined by the supplier. Bovine pancreatic
α-chymotrypsin, hen egg-white lysozyme, equine heart cytochrome
c(Cyt c), micrococcus cells, and poly(vinyl)alcohol (PVA, 87%–89% hy-
drolyzed with a MW of 13,000–23,000) were from Sigma-Aldrich (St.
Louis, MO). Acetonitrile (ACN, HPLC grade) was from Fisher Scientiﬁc
(Pittsburgh, PA). Succinyl-Ala-Ala-Pro-Phe-p-nitroanilide was from
Bachem Laboratories (Torrens, CA).
2.2. Protein precipitation and encapsulation
Protein nanoparticles were obtained using a similar method as
described byWeber et al. [25]. Brieﬂy, lysozyme and α-chymotrypsin
were solvent-precipitated from 0.8 and 1ml of aqueous solutions
at concentrations of 25 and 15mg/ml, respectively, by adding the
water-miscible solvent acetonitrile at a 1:4 volume ratio. The result-
ing protein suspension was stirred for 5min with a magnetic stir bar.
PLGA was dissolved in acetonitrile at 190 and 28.5mg/ml and 2 and
10ml added to the lysozyme and α-chymotrypsin suspensions, re-
spectively. The resulting mixtures (6 and 14ml) were added directly
through a syringe needle into 240 and 560ml of a 10% PVA solution
under stirring (60ml/min) with a magnetic stir bar (5.08 cm length).
The volume ratio of dispersing phase to diffusing phase was 1:40.
Polymer nanoprecipitationwas immediately visible upon injection of
the protein suspensions. The PLGA nanoparticles formedwere imme-
diately centrifuged for 10minat 8000 rpm, the supernatant discarded,
and the pellet re-suspended in distilled water. This washing step was
thrice repeated and the samples subsequently freeze-dried by ﬁrst
rapidly freezing them in liquid nitrogen followed by lyophilization
at a condenser temperature of −45 ◦C and a pressure of <60μm of
Hg [26]. Cyt-c encapsulationwas performed using the same optimum
conditions established by us for lysozyme since it has a similar size
and net charge.
2.3. Determination of the precipitation yield
After protein nanoprecipitation, the resulting protein suspension
was centrifuged at 5000 rpm for 10min. The supernatant was dis-
carded and the pellet vacuum dried for 30min. Protein concentration
and protein aggregates in the pellet were determined as described
by us in detail [26–29]. In brief, the protein pellet was suspended
in 2ml of potassium phosphate buffer for 2h to dissolve the buffer-
soluble fraction. The samples were then subjected to centrifugation
at 5000 rpm for 5min and the supernatant used to determine the
concentration of soluble protein. Next, 1ml of 6M urea was added to
the pellet to dissolve the buffer-insoluble protein fraction and used to
determine the concentration of aggregated protein by measuring the
UV absorbance at 280nm. The precipitation yieldwas calculated from
the actual and theoretical quantity of protein recovered after nano-
precipitation and rehydration. The experiments were performed in
triplicate, the results averaged, and the standard deviations calcu-
lated.
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Table 1
Properties of the protein precipitates using acetonitrile (ACN) and acetone as desolvat-
ing agent.*
Protein/solvent
Precipitation
yield (%)
Insoluble
aggregates (%) Residual activity (%)
Lysozyme
ACN 79 ± 4 0 ± 0 96 ± 8
Acetone 54 ± 28 6 ± 3 81 ± 3
α-Chymotrypsin
ACN 80 ± 5 3 ± 2 73 ± 1
Acetone 82 ± 3 1 ± 2 75 ± 8
∗ Protein concentration: 10mg/ml; volume ratio of water-to-organic solvent: 1:4.2.4. Dynamic light scattering
The size of protein nanoparticles and PLGA nanospheres was de-
termined by dynamic light scattering using a DynaPro Titan with Mi-
croSampler from Wyatt Technology Corporation (Santa Barbara, CA)
as described by us in detail [20]. Protein particles were measured as a
suspension in acetonitrile and the PLGA nanospheres as a suspension
in water at 100% power intensity. Data analysis was performed using
the Dynamic 6.7.6 software suppliedwith the instrument. The instru-
ment was periodically calibrated using BSA as a standard. In the past,
we found that scanning electron microscopy images and size data
from dynamic light scattering were consistent [20].
2.5. Determination of actual protein loading and encapsulation
efﬁciency
The actual protein loading of nanosphereswas determined follow-
ing amethodology developed in our laboratory [27]. In brief, 20mg of
PLGA nanospheres were dissolved in 2ml of ethyl acetate and stirred
for 2h followed by centrifugation at 9000 rpm for 10min. The super-
natantwasdiscarded and thepellet vacuumdried for 30min. This pel-
let, consisting mostly of protein, was suspended in 2ml of potassium
phosphate buffer for 2h to dissolve the buffer-soluble protein frac-
tion. The samples were then subjected to centrifugation at 9000 rpm
for 10min and the supernatant used to determine the concentration
of soluble protein. Next, 1ml of 6M urea was added to the pellet to
dissolve the water-insoluble protein fraction. In all cases, a clear so-
lution without noticeable light scattering was obtained and used to
determine the concentration of aggregated protein by measuring the
UV absorbance at 280nm and by BCA assay at 562nm. The encapsula-
tion efﬁciency was calculated from the actual and theoretical loading
of protein in the nanospheres. The experiments were performed in
triplicate, the results averaged, and the standarddeviations calculated
to highlight the reproducibility of the experiments.
2.6. Determination of enzyme activity
To determine the enzyme activity after encapsulation, ethyl ac-
etate was used to dissolve PLGA because it does not cause enzyme
inactivation in theprocess [27]. Activity ofα-chymotrypsinwasdeter-
mined using succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as the substrate
[28]. The reactionwas carried out in 1ml of 0.1M Tris-HCl buffer con-
taining 0.05mg/ml enzyme, 0.35mM substrate, and 10mM CaCl2 at
pH 7.8 and our data for α-chymotrypsin as purchased are compara-
ble to those reported [28]. The activity of 0.01mg/ml lysozyme was
determined by measuring the decrease in turbidity at 450nm of a
0.015% (w/v) suspension of Micrococcus lysodeikticus cells in 1ml of
66mM potassium phosphate buffer at pH 6.2 and 25 ◦C as described
by us [29]. The peroxidase-like activity of Cyt-c which is not a natural
enzyme was obtained as described [30]. Brieﬂy, the reaction was fol-
lowed at 415nm using 0.25ml of 0.01mg/ml Cyt-c, 0.2ml of 300mM
H2O2, and 0.55ml of 0.05mM2,2
′-azino-bis(3-ethylbenzothiazoline-
6-sulphonic acid) in 20mM potassium phosphate buffer at pH 7. The
data obtained by us for commercial Cyt-c are comparable to those
reported in the literature [30].The activity was obtained by plotting the time-dependent ab-
sorbance changes vs. time. The linear portions of the graphs at less
than 10% substrate conversion were used to obtain the initial veloci-
ties (V0). In all cases the speciﬁc activity (mM of substrate converted
into product per min and per mg of protein) was calculated. The ex-
periments were performed in triplicate and the results averaged and
the standard deviations calculated.
2.7. In vitro release studies
In vitro release studies were conducted as described by us in the
past [26–29]. In brief, nanospheres (30mg) were placed in 1ml of
10mM phosphate buffered saline (PBS) at pH 7.3 and incubated at
37 ◦C. At pre-determined times (typically every 24h) the supernatant
was removed after a short centrifugation. The concentration of the
released protein in the supernatant was determined by absorbance
measurement at 280nm (the absorbance was corrected by the very
small absorbance produced by degrading empty PLGA nanospheres).
The concentration of the released protein was used to construct cu-
mulative release proﬁles. Release experiments were performed at
least in triplicate, the results averaged, and the standard deviations
calculated.
2.8. Cell culture
HumanHeLa epithelial adenocarcinoma cells (American Type Cul-
ture Collection (ATCC), Manassas, VA, catalog number CCL-2) were
cultured in Eagle’s Minimum Essential Medium (Invitrogen Corp.)
supplemented with 10% (v/v) fetal bovine serum (FBS; Invitrogen
Corp.), penicillin (100U/ml), and 1% glutamine as described by the
ATCC. Cells were maintained at 37 ◦C in a humidiﬁed atmosphere of
5% CO2 and 95% air.
2.9. In vitro cell studies – non-radioactive cell poliferation assay
The non-radioactive cell proliferation assay was performed ac-
cording to the manufacturer instructions (Promega). HeLa cells were
seeded into 96-well plates at 7.5×104 cells/well and incubated at
37 ◦C for 24h. Then, cells were subjected to medium replacement
containing 1% FBS and incubated overnight. Various concentrations
of Cyt-c-PLGA NPs dispersed in the cell culture medium were added
to cells followed by further incubation at 37 ◦C for 24, 48, 72, or 96h.
The tested concentrations of Cyt-c-PLGA NPs are equivalent to Cyt-c
concentrations of 0.61, 1.21, 3.10, 6.19 and 12.38μg/ml. Control ex-
periments were performed using blank PLGA NPs. At the day of the
experiment, the cells were washed once with PBS and 100μl fresh
mediumwas added. Background values were recorded at 492nm us-
ing a microplate reader. Then, cells were treated with 20μL of MTS
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoleum; 5μg/μl) for
1h and the absorbance was measured at 492nm. The results were
based on at least three independent experiments and the data aver-
aged.
2.10. Statistical analysis
All experiments were performed at least in triplicate, the data
averaged, and the standard deviations calculated. The standard devi-
ations are included in all tables as ± values. To establish statistical
signiﬁcancewhen comparingmultiple groupswe used one-waymul-
tiple Tukey comparison post-test ANOVA. A P value of <0.05 was
considered statistically signiﬁcant.
82 Moraima Morales-Cruz et al. / Results in Pharma Sciences 2 (2012) 79–85
Table 2
Characterization of the nano-precipitation results at various protein concentrations at a 1:4 volume ratio of water-to-acetonitrile.
Protein Concentration (mg/ml) Precipitation yield (%) Insoluble aggregates (%) Residual activity (%) Diameter (nm)
Lysozyme 10 70 ± 11 2 ± 1 87 ± 5 86 ± 16
20 95 ± 4 1 ± 0 83 ± 1 92 ± 15
30 99 ± 1 1 ± 1 96 ± 2 168 ± 14
α-Chymotrypsin 10 77 ± 5 0 ± 0 78 ± 0 66 ± 16
20 83 ± 3 0 ± 0 100 ± 1 174 ± 16
30 83 ± 4 0 ± 0 100 ± 2 200 ± 12
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Table 3
Effect of the emulsiﬁer on selected properties of lysozyme-loaded PLGA nanospheres.*
Dispersing
phase
Encapsulation
efﬁciency (%)
Protein
aggregates (%) Residual activity (%)
Water 48 ± 23 0 ± 0 100 ± 12
10% PEG <10 n.d. n.d.
5% PVA 58 ± 28 3 ± 5 88 ± 21
10% PVA 71 ± 15 0 ± 5 90 ± 3
∗ Lysozyme concentration: 25mg/ml; volume ratio ofwater to ACN: 1:4; concentration
of PLGA 65:35 in acetonitrile: 28.5mg/ml; total volume of the diffusing phase: 12ml,
and for the dispersing phase: 150ml; theoretical loading: 2% (w/w).. Results and discussion
.1. Development and optimization of a two-step nanoprecipitation
ethod
.1.1. Protein nanoprecipitation
First we explored the effects of different desolvating agents, dif-
erent excipients, and the protein concentration on the protein nano-
recipitation process using lysozyme and α-chymotrypsin as model
roteins. In order to optimize the processing conditions, the pre-
ipitation yield, protein particle size, and residual enzyme activity
ere determined.While protein precipitateswere obtainedwith ace-
onitrile and acetone, propanol and ethanol were inefﬁcient for both
nzymes (data not shown, for conditions see footnotes in Table 1).
e also tested the addition of common stabilizing excipients on the
rocess outcome (poly(ethylene glycol) with a MW of 8000, methyl-
-cyclodextrin, and trehalose at a 1:1 excipient-to-protein weight
atio). It was found that excipients did not improve the process out-
ome in the case of lysozyme and hindered precipitation in the case
f α-chymotrypsin. We therefore did not employ excipients subse-
uently to avoid such complications—.
Focusing on the best solvents identiﬁed, ACN and acetone, the
utcome of the nanoprecipitation process was characterized in detail
Table 1). While the precipitation efﬁciency was comparable for both
olvents, acetonitrile caused less enzyme aggregation and inactiva-
ion in the case of lysozyme. This solvent was therefore chosen for all
ubsequent work.
In order to further optimize theprecipitation conditions,wevaried
he volume ratio of acetonitrile-to-water. Similar to Weber et al. [25]
ho used ethanol as desolvating agent, we found that a 1:4 water-
o-ACN volume ratio was sufﬁcient to precipitate both proteins (data
ot shown).
Next, we tested the effect of the protein concentration on pre-
ipitation results (Table 2). The precipitation yield and particle size
ncreased at increasing protein concentration under otherwise con-
tant precipitation conditions. While for both proteins, no signiﬁcant
mounts of buffer-insoluble aggregateswere formed regardless of the
rotein concentration, the residual activity increased at increasing
rotein concentration.We interpret this as an indication, that protein
olecules close to the solvent-interface are more prone to denatu-
ation than molecules buried in the interior of the precipitates. Such
bservations have been made before in solid-in-oil-in-water encap-
ulation procedures [28]. It is apparent that protein concentrations of
0–30mg/ml give optimum results. For α-chymotrypsin concentra-
ions higher than 40mg/ml, unstable suspensions of the precipitated
rotein resulted and thus did not allow for the subsequent encapsu-
ation process.
We can surmise from the above that similar to ﬁndings by Giteau
t al. [19], a variety of precipitation conditions was identiﬁed by us
eading to nano-particulate enzyme precipitates without causing ac-
ivity loss or formation of buffer-insoluble aggregates.
.1.2. Protein nanoparticle encapsulation
After optimizing the protein precipitation conditions, we pro-
eeded to encapsulate the model proteins into PLGA nanospheres.Previously, Giteau et al. precipitated proteins to ensure their stabil-
ity upon subsequent encapsulation within PLGA microspheres using
a solid-in-oil-in-water (s/o/w) technique [19]. After protein precipi-
tation with glycofurol, proteins were centrifuged and the pellet sus-
pended in acetonitrile (ACN) containing the polymer and encapsu-
lated within PLGA microspheres. Our method used the same desol-
vating agent (ACN) to precipitate the protein and to dissolve the poly-
mer. Additionally, several steps in the encapsulation procedure were
changed systematically to assure obtaining nanosized PLGA spheres
with high protein loading while aiming at avoiding enzyme inactiva-
tion and aggregation. Initially, we selected PLGA with a co-polymer
ratio of 65% lactic acid and 35% glycolic acid, a theoretical loading
of 2% (w/w), and ACN as the diffusing phase. We tested two com-
monly used emulsifying agents, namely, poly(vinyl alcohol) (PVA)
and poly(ethylene glycol) (PEG, MW = 8000) using a set of deﬁned
conditions (Table 3) [28]. It was found that the highest encapsulation
efﬁciency of ca. 70% was achieved using 10% of PVA without compro-
mising protein stability.
We tried to increase the protein loading to 5%, but surprisingly
the encapsulation failed when the protein nanoparticles suspended
in PLGA solution were added to the PVA solution. However, using
PLGA with a co-polymer ratio of 50:50 resulted in nanoencapsula-
tion, but the encapsulation efﬁciency needed improvement. When
we increased the volume of the diffusing phase to accomplish faster
particle hardening, the encapsulation efﬁciency increased substan-
tially to >80% at a 1:40 volume ratio of dispersing-to-diffusing phase
(Table 4). We also tested the polymer concentration in this context. It
has been shown that a higher polymer concentration leads to higher
encapsulation efﬁciency and larger size of the nanoparticles [31,32].
At a high PLGA concentration, the viscosity of the diffusing phase in-
creases which should result in improved encapsulation by reduction
of lysozyme nanoparticles leaking into the dispersing phase. Indeed,
we found increasing lysozyme encapsulation efﬁciency at increasing
polymer concentration as expected (Table 5). In a similar fashion en-
capsulation efﬁciency was improved for α-chymotrypsin. Changing
the polymer concentration proved only somewhat successful in this
case, possibly because at increased PLGA concentrations the polymer
shell thickness also increased [33]. The encapsulation efﬁciency re-
mained with amaximum of 30% too low for practical purposes (Table
5). Reducing theparticle size ofα-chymotrypsin by employing a lower
protein concentration of 15 mg/ml (Table 2) resulted in an improved
encapsulation efﬁciency of 74% (Table 6).
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Table 4
Effect of the ratio of dipersing-to-diffusing phase on the encapsulation efﬁciency of
lysozyme in PLGA nanoparticles.*
Ratio of dispersing phase to
diffusing phase Encapsulation efﬁciency (%)
1:10 9 ± 3
1:20 49 ± 9
1:30 71 ± 7
1:40 84 ± 8
∗ Protein concentration: 25mg/ml; volume ratio between water and ACN: 1:4; PLGA
50:50 concentration in ACN: 90mg/ml; theoretical loading: 5% (w/w).
Table 5
Effect of different polymer concentrations on the protein encapsulation efﬁciency in
PLGA nanopheres.*
Batch
Concentration
of PLGA 50:50
in ACN (mg/ml) Encapsulation efﬁciency (%)
Lysozyme α-Chymotrypsin
1 38 26 ± 6 11 ± 4
2 63 45 ± 12 24 ± 4
3 95 68 ± 7 30 ± 1
4 190 94 ± 5 23 ± 3
∗ Protein concentration: 25mg/ml; volume ratio of water to organic solvent: 1:4;
polymermass: 380mg; volume ratio of dispersing-to-diffusingphase: 1:40; theoretical
protein loading: 5%.
Table 6
Effect of the polymer concentration on α-chymotrypsin encapsulation efﬁciency in
PLGA nanospheres.*
Batch
Concentration of PLGA
50:50 in ACN (mg/ml)
Encapsulation efﬁciency
(%)
1 28.5 74 ± 4
2 47.5 49 ± 9
3 71.25 48 ± 4
4 142.5 38 ± 18
∗ Protein concentration: 15mg/ml; volume ratio between water and organic solvent:
1:4; polymer mass: 285mg; volume ratio of dispersing-to-diffusing phase: 1:40ml;
theoretical protein loading: 5%.
Table 7
Properties of lysozyme and α-chymotrypsin-loaded PLGA nanospheres produced by
two-step nanoprecipitation.*
Protein
Encapsulation
efﬁciency
(%)
Insoluble
aggregates
(%)
Residual
activity (%) Diameter (nm)
Lysozyme
94 ± 5 0 ± 0 100 ± 8 336 ± 40
α-Chymotrypsin
74 ± 4 14 ± 17 49 ± 2 440 ± 16
∗ The samples correspond to the conditions described for the batch 4 in Table 5 and
batch 1 in Table 6.
Table 8
Properties of Cyt-c after precipitation and encapsulation in PLGA nanospheres.*
Precipitation Encapsulation
Precipitation
efﬁciency (%)
81 ± 1 N/A
Encapsulation
efﬁciency (%)
N/A 72 ± 2
Insoluble aggregates
(%)
0 ± 0 5 ± 3
Residual activity (%) 96 ± 6 98 ± 3
Particle size (nm) 80 ± 17 342 ± 62
∗ For conditions see batch 4, Table 5.The data show how sensitive the results respond to encapsulation
conditions in this method highlighting the fact that encapsulation
likely has to be optimized in a similar fashion as described here for
other proteins. However, there are only a few processing parameters
requiring adjustment and the process is straight forward and repro-
ducible as demonstrated by the small standard deviations obtained
for encapsulation parameters under optimized conditions.
The optimum conditions to encapsulate lysozyme and α-
chymotrypsin in PLGA nanoparticles are summarized in Table 7. The
size of the protein loaded PLGA particles obtained by dynamic light
scattering was ca. 300–400nm in diameter (Table 7). However, while
lysozyme encapsulation afforded a highly active enzyme, substan-
tial enzyme inactivation and formation of buffer-insoluble aggregates
were observed forα-chymotrypsin. The formation of buffer-insoluble
aggregates and loss in speciﬁc activity found for α-chymotrypsin
is similar to results obtained before upon α-chymotrypsin encap-
sulation in PLGA microspheres using a s/o/w technique [27,28,34–
36]. The use of stabilizing additives (e.g., methyl-β-cyclodextrin or
poly(ethylene glycol)) was necessary in the latter case to preserve
protein integrity. Such strategies have to be developed for the new
two-step nanoprecipitation procedure as well.
3.1.3. Cytochrome c-loaded PLGA nanoparticles
Having accomplished protein loaded nano-sized PLGA particles,
we tested the development of the sustained release nanoparticles
into an application platform. We selected Cyt-c as model protein be-
cause it has been employed in experiments geared towards bettercancer treatment options [24]. The size of our particles makes them
potentially useful in passive and also active targeting of cancer tis-
sues [37,38]. For example, Santra et al. [24] demonstrated recently the
therapeutic potential of Cyt-c in nanoparticles by their capability to
induce apoptosis in lung carcinoma cells after uptake by the cells by
endocytosis. However, their vehicle consisted of a water-soluble hy-
perbranched polyhydroxyl polymer not approved inmedical applica-
tions. In contrast, our nanoparticles employ an already FDA approved
and commercially available polymer (PLGA) and a straight forward
encapsulation method.
We hypothesized that encapsulation of Cyt-c via the two step
nanoprecipitation method should work using the optimum condi-
tions identiﬁed for lysozyme (Table 7) because both proteins have a
similar molecular weight (12 and 14kDa, respectively) and are basic
[39]. The encapsulation efﬁciency for Cyt-c was with 72% is similar to
that obtained for lysozyme under identical conditions (Table 8). The
peroxidase activity of Cyt-c was comparable to values prior to precip-
itation and encapsulation and only few aggregates were formed in-
dicating good preservation of structural integrity during the process.
The size of the particles obtained was 340nm and thus potentially
useful to enable passive delivery to cancer tissues based on the EPR
effect [37,38].
In vitro release of Cyt-c from the PLGA nanoparticles showed an
initial “burst” release within 24h that was reasonably small with ca.
20% (Fig. 2). Burst release values of>20% are frequently found for such
systems, in particular when nanosized systems are being used [40].
During a 100-day incubation period, Cyt c was released completely
from the nanospheres. Since the release was slow, the amount of
protein released per day was small and the residual activity during
release could not bemeasuredwith accuracy. Future experiments us-
ing cell cultures and animalmodels will shed light into the bioactivity
of the developed system. However, since 100% of the protein was re-
leased, we can exclude the formation of buffer-insoluble Cyt-c during
the release period.
3.2. Cyt-c-PLGA nanoparticle cytotoxic effects in cancer cells
Since there are some reports that PLGA nanoparticles could be
internalized by cells, we investigated whether the Cyt-c-PLGA NPs
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Fig. 2. In vitro release proﬁle of Cyt-c from PLGA nanospheres prepared by two step
nanoprecipitation.
Fig. 3. Comparison of the cell viability of HeLa cells treated with Cyt-c encapsulated in
PLGAnanoparticles (NPs) vs. empty PLGANPs after 72 (a) and96h (b) of incubation. The
numbers 1–5 on the y-axis corresponds to 0.61, 1.21, 3.10, 6.19, and 12.38μg/ml Cyt-c,
respectively, in case of Cyt-c loaded PLGA NPs. Empty PLGA NPs were adjusted to the
same PLGA concentrations as the corresponding Cyt-c-loaded PLGA NPs. Cyt-c-PLGA
NPs induced a signiﬁcant reduction in cell viability after 72 and 96h of incubation for
the 12.38mg/ml protein concentration, whereas the PLGA NPs showed no signiﬁcant
cytotoxicity.
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iould be toxic to cancer cells. We selected a human cervical cancer
ell line (HeLa) as a model system and incubated the cells for 24, 48,
2, and 96h at 37 ◦C under 5% CO2 with various concentrations of
rug-loaded and empty PLGA nanoparticles and determined the cell
iability (Fig. 3). It was observed that after 72h of incubation, the
eLa cells treated with Cyt-c-PLGA NPs had a signiﬁcantly reduced
iability for the highest Cyt-c concentration used (12.38mg/ml). In
ontrast, PLGA nanospheres without the drug had no effect on cell
iability in agreement with the biocompatible nature of the PLGA
olymer family. Establishment of biocompatibility of the PLGA NPs is
mportant in the development of them as drug delivery systems.
It has to be pointed out, however, that the effect of the drug-
oaded delivery system on cell viability was too low to be clinically
elevant. It is likely that PLGA NPs are not taken up effectively and
hus Cyt-c is not being effectively delivered to the cell cytoplasm in
greementwith recent data [41].Wecan conclude from this that PLGA
Ps have to be eithermodiﬁedwith a homing ligand or release a drug
oupled to a homing ligand to enable uptake by receptor-mediated
ndocytosis. We are currently working on transforming this system
n this direction.
. Conclusions
Nanosizeddelivery systemsholdpromise in improvingproteinde-
ivery, i.e., to target tumors and inﬂamation. A convenient method to
ccomplish nanosized polymer particles is by one-step nanoprecip-
tation. However, encapsulation of proteins into PLGA nanospheresby nanoprecipitation was inefﬁcient prior to our work and/or in-
volved the solvent DMSOwhich irreversibly denatures most proteins
[17,18,42,43]. To overcome these problems, we developed a two-step
nanoprecipitation method to allow for efﬁcient protein encapsula-
tion into PLGA nanospheres without causing irreversible functional
changes. Cell viability studies using HeLa cells demonstrate excellent
biocompatibility of the PLGA nanospheres obtained. Furthermore,
we demonstrate reproducible encapsulation of the model proteins
lysozyme, α-chymotrypsin, and Cyt-c into PLGA nanospheres. Opti-
mization of the processing parameters involved in the new two-step
nanoprecipitation method enabled obtaining high encapsulation ef-
ﬁciencies. While encapsulation of lysozyme and Cyt-c via the two-
step nanoprecipitation method did not lead to the formation of in-
soluble aggregates or activity loss, signiﬁcant enzyme inactivation
and formation of buffer-insoluble aggregates were observed for α-
chymotrypsin. Future studies in our laboratory will be directed to-
wards minimizing this problem.
Admittedly, as one reviewer pointed out to us, the results obtained
with the therapeutic protein seem not sufﬁcient to justify the prepar-
ative efforts. However, we feel that our work and the results obtained
constitute a ﬁrst signiﬁcant step into the direction of solving a com-
plex problem. Our work clearly demonstrates the feasibility of ob-
taining nanosized biocompatible protein delivery systems with good
yield and reasonableprotein stability. This should support approaches
aiming at targeted protein delivery using the enhanced permeabil-
ity and retention (EPR) effect to deliver pharmaceutical proteins to
tumors or inﬂammation sites. This approach has to be augmented
by targeted delivery strategies aimed at enabling endocytosis of the
nanoparticles, e.g., by attaching folate to their surface.
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